Vosevi (sofosbuvir-velpatasvir-voxilaprevi)

Vosevi (sofosbuvir-velpatasvir-voxilaprevi) wholesale

Vosevi (Sofosbuvir-Velpatasvir-Voxilaprevi) Wholesale

Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevi)  wholesaler,

VOSEVI (SOFOSBUVIR/VELPATASVIR/VOXILAPREVI) DESCRIPTION:

Vosevi is a combination of sofosbuvir, velpatasvir, and voxilaprevi:

  • sofosbuvir – a nucleotide polymerase inhibitor that interferes with the reproduction of the genetic material of the hepatitis C virus
  • velpatasvir – an NS5A (hepatitis C virus non-structural protein 5A) inhibitor that works by interfering with a protein needed by the virus
  • voxilaprevir – a protease inhibitor that interferes with the production of the pieces needed to build new virus particles

On July 18, 2017 the U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs – sofosbuvir and velpatasvir – and a new drug, voxilaprevir.

VOSEVI (SOFOSBUVIR/VELPATASVIR/VOXILAPREVI) INDICATIONS:

VOSEVI is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, velpatasvir, an HCV NS5A inhibitor, and voxilaprevir, an HCV NS3/4A protease inhibitor, and is indicated for the treatment of adult patients with chronic HCV infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have (1, 2.2, 14):

• genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor.

• genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. 

Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor.

DOSAGE FORM & STRENGTH:

  • VOSEVI (Sofosbuvir 400 mg/Velpatasvir 100 mg/Voxilaprevi100 mg) 

Rasso Swiss Pharma is a VOSEVI wholesaler distributor, supplier. In addition to VOSEVI Rasso Swiss Pharma can supply generic (Sofosbuvir/Velpatasvir/Voxilaprevi) at much cheaper prices. 

<< Back to products